Monoclonal antibody (mAb) manufacturing processes typically contain several steps that are evaluated for their ability to remove or inactivate viruses that may be present in the process material. The ...
Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have recently developed a neotype lysosomal trap for clearing viruses and variants. This lysosomal "TRAP" ...
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient ...
Brown joined Charles River in November 2022 after completing his bachelor’s degree from the University of Scranton. Brown started his journey in the Viral Clearance Department at the Wayne, PA site as ...
More than 40 million people worldwide are living with HIV-1, which continues to be a major global health challenge due to its ability to persist silently within immune cells, evading complete ...
The US government has set a goal of achieving viral clearance in 80% of patients by 2030. The study’s authors say the report shows there is still much work to be done to increase access to DAAs and ...
The key obstacle against the cure of human and simian immunodeficiency virus (HIV/SIV) infections is the reservoir of proviruses, which are robustly incorporated into the genomes of host CD4+ T cells.
Schematic for showing lysoTRAP programmed performance in capturing, internalizing, and degrading multiple viruses and variants for virus clearance in multiple virus challenge models. Researchers from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results